DPP-4 inhibitors reduced HbA1c by an average of 0.77% (95% CI -0.82 to -0.72%), with baseline HbA1c and fasting glucose explaining 58% of the variance in response.
Meta-Analysis (n=24,163)
Do DPP-4 inhibitors reduce HbA1c in adults with type 2 diabetes?
Baseline HbA1c and fasting glucose explain most of the variance in HbA1c reduction with DPP-4 inhibitors, allowing for estimation of response via a nomogram.
OBJECTIVES: To develop a nomogram for estimating the glycated haemoglobin (HbA1c) response to different dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes. DESIGN: A systematic review and meta-analysis of randomised controlled trials (RCTs) of DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, linagliptin and alogliptin) on HbA1c were conducted. Electronic searches were carried out up to December 2013. Trials were included if they were carried out on participants with type 2 diabetes, lasted at least 12 weeks, included at least 30 participants and had a final assessment of HbA1c. A random effect model was used to pool data. A nomogram was used to represent results of the metaregression model. PARTICIPANTS: Adults with type 2 diabetes. INTERVENTIONS: Any DPP-4 inhibitor (vildagliptin, sitagliptin, saxagliptin, linagliptin or alogliptin). OUTCOME MEASURES: The HbA1c response to each DPP-4 inhibitor within 1 year of therapy. RESULTS: We screened 928 citations and reviewed 98 articles reporting 98 RCTs with 100 arms in 24 163 participants. There were 26 arms with vildagliptin, 37 with sitagliptin, 13 with saxagliptin, 13 with linagliptin and 11 with alogliptin. For all 100 arms, the mean baseline HbA1c value was 8.05% (64 mmol/mol); the decrease of HbA1c from baseline was -0.77% (95% CI -0.82 to -0.72%), with high heterogeneity (I(2)=96%). Multivariable metaregression model that included baseline HbA1c, type of DPP-4 inhibitor and fasting glucose explained 58% of variance between studies, with no significant interaction between them. Other factors, including age, previous diabetes drugs and duration of treatment added low predictive power (<1%). The nomogram estimates the absolute HbA1c reduction from baseline using the type of DPP-4 inhibitor, baseline values of HbA1c and fasting glucose. CONCLUSIONS: Baseline HbA1c level and fasting glucose explain most of the variance in HbA1c change in response to DPP-4 inhibitors: each increase of 1.0% units HbA1c provides a 0.4-0.5% units greater fall.
Esposito et al. (2015) conducted a meta-analysis in type 2 diabetes (n=24,163). DPP-4 inhibitors was evaluated on HbA1c response to each DPP-4 inhibitor within 1 year of therapy (95% CI -0.82 to -0.72). DPP-4 inhibitors reduced HbA1c by an average of 0.77% (95% CI -0.82 to -0.72%), with baseline HbA1c and fasting glucose explaining 58% of the variance in response.